Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly.
The metabolic side effects of atypical antipsychotics (AAPs) have been widely studied in younger populations, but research investigating these sequelae in the elderly is lacking. This article reviews the available literature examining the use of AAPs in the elderly, evaluating their association with...
| Published in: | Drugs & Aging Vol. 31; no. 3; pp. 159 - 185 |
|---|---|
| Main Authors: | , , , |
| Format: | research systematic review tables/charts Journal Article |
| Published: |
Springer Nature
Mar2014
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104034213&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104034213 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1170229X C5B jtl: Drugs & Aging issn: 1170229X maglogo: N pubinfo: dt: Mar2014 vid: 31 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104034213 94694334 10.1007/s40266-014-0152-x NLM24477569 104034213 ppf: 159 ppct: 26 formats: fmt: @attributes: type: P tig: atl: Atypical Antipsychotic-Induced Metabolic Disturbances in the Elderly. aug: au: Guenette, Melanie Chintoh, Araba Remington, Gary Hahn, Margaret affil: Centre for Addiction and Mental Health, 250 College Street Toronto M5T 1R8 Canada sug: subj: Metabolic Diseases Chemically Induced Antipsychotic Agents Adverse Effects Metabolic Diseases Etiology Human Antipsychotic Agents Classification Systematic Review PubMed Olanzapine Pharmacodynamics Quetiapine Pharmacodynamics Risperidone Pharmacodynamics Blood Glucose Drug Effects Aged Aged: 65+ years ab: The metabolic side effects of atypical antipsychotics (AAPs) have been widely studied in younger populations, but research investigating these sequelae in the elderly is lacking. This article reviews the available literature examining the use of AAPs in the elderly, evaluating their association with weight gain and changes in blood glucose and lipid parameters. We find a relative paucity of studies in this area; while some data highlight significant, collective changes in metabolic parameters, the majority suggests an apparent low vulnerability to these side effects. We conclude that the risk and clinical implications of unfavorable metabolic changes in the elderly being treated with AAP medications remain largely undetermined, and we caution against drawing firm conclusions based on the available data. The conflicting evidence leaves us recommending that metabolic monitoring be implemented, with regular follow-up as advocated in other populations. pubtype: Academic Journal doctype: research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|